KRYS News and Press, Krystal Biotech Inc. From 03/01/24

2024-03-01 07:31:00 ET Technically, there is no upper limit to how much money investors can make from stocks in five years, but turning $1,000 into $2,500 is no easy task. That requires a compound annual growth rate (CAGR) of 20.1%, more than double the S&P 500's historical growth rate....

PITTSBURGH, Feb. 28, 2024 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), a commercial-stage biotechnology company, today announced that the Company will participate in the TD Cowen 44 th Annual Health Care Conference, which takes place in Boston on...

A look at the top 10 most actives in the United States SoundHound AI Inc. (SOUN) rose 46.7% to $5.75 on volume of 212,903,866 shares Akili Inc. (AKLI) rose 104.1% to $0.4523 on volume of 128,377,553 shares Charge Enterprises Inc. (CRGE) rose 8.7% to $0.0586 on volume of 119,330,728 shares...

A look at the top 10 most actives in the United States SoundHound AI Inc. (SOUN) rose 44.6% to $5.6701 on volume of 178,857,693 shares Akili Inc. (AKLI) rose 151.8% to $0.55799 on volume of 116,391,092 shares Charge Enterprises Inc. (CRGE) rose 9.8% to $0.0592 on volume of 114,988,307 sha...

Krystal Biotech, Inc. (NASDAQ: KRYS) is one of today's top gainers. The company's shares have moved 35.6% on the day to $150.96. Krystal Biotech, Inc., a clinical stage biotechnology company, engages in the field of redosable gene therapy to treat serious rare diseases in the United States. It...

•  Net product revenue of $42.1M in 4Q and $50.7M for the year •  New England Journal of Medicine publication of the use of B-VEC eyedrop formulation •  Reached alignment with FDA to enable approval of B-VEC eyedrop f...

SUIC Worldwide Holdings Ltd (SUIC) is expected to report for Q4 2023 QuantaSing Group Limited (QSG) is expected to report $0.11 for Q2 2024 uniQure N.V. (QURE) is expected to report $-1.54 for Q4 2023 Albany International Corporation (AIN) is expected to report $0.84 for Q4 2023 I...

2024-02-23 14:22:55 ET More on Krystal Biotech Krystal Biotech: Ready For Launch Krystal Biotech's Vyjuvek Impresses Early On, Bolsters Prospects Krystal Biotech, Candel, Edgewise gain after FDA fast track tags Krystal Biotech added to Evercore’s Tacti...

2024-02-20 13:26:56 ET Summary Krystal Biotech, Inc. has gained 50% in the past year after receiving FDA approval for its gene therapy to treat dystrophic epidermolysis bullosa. The company's pipeline also includes early-stage treatments for oncology and cystic fibrosis, with some...

PITTSBURGH, Feb. 20, 2024 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), a commercial-stage biotechnology company, will report its fourth quarter and full year 2023 financial results on Monday, February 26, 2024, prior to the open of U.S. mark...